According to a recent LinkedIn post from C8 Health, company-affiliated researchers presented multi-institution neuraxial anticoagulation protocol research at an ASRA meeting. The study reportedly used C8’s AI to compare protocols across five hospitals against 96 ASRA 5th-edition recommendations and found that over 60% of items were inconsistent or missing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that high-evidence, long-standing recommendations were generally aligned, while newer or lower-evidence elements, such as specific drug thresholds and timing, showed greater divergence. This framing positions C8’s AI as a tool that can surface guideline gaps and potentially support hospital quality improvement and risk management.
As shared in the post, the AI capability used in the study underpins Evidence Compare, a functionality expected to debut on the C8 platform later this year. For investors, the introduction of Evidence Compare could enhance the platform’s value proposition for anesthesiology and perioperative care customers, potentially supporting adoption, pricing power, and pipeline opportunities, particularly through collaborations like the one referenced with the ASA.